Free tool
FAERS Monitor: Bortezomib
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212782 or its brand name (Bortezomib, Bortezomib). Reports on generic versions are filed under their own applications.
Reports
33,996
Serious
32,180
95% of reports
Hospitalization
10,537
Death reported
6,006
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- plasma cell myeloma5,249
- off label use3,253
- drug ineffective2,307
- neuropathy peripheral1,904
- thrombocytopenia1,807
- death1,591
- pneumonia1,575
- neutropenia1,428
- diarrhoea1,414
- fatigue1,162
- anaemia1,136
- disease progression1,072
- pyrexia980
- nausea925
- toxicity to various agents918
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 25 |
| 2006 | 17 |
| 2007 | 37 |
| 2008 | 78 |
| 2009 | 161 |
| 2010 | 248 |
| 2011 | 313 |
| 2012 | 409 |
| 2013 | 556 |
| 2014 | 800 |
| 2015 | 1,311 |
| 2016 | 1,077 |
| 2017 | 1,232 |
| 2018 | 1,699 |
| 2019 | 2,521 |
| 2020 | 3,037 |
| 2021 | 3,110 |
| 2022 | 3,923 |
| 2023 | 3,918 |
| 2024 | 3,760 |
| 2025 | 3,243 |
| 2026 | 2,506 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,020,163 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 5,249 | 96.0 | 93.4 | 427,871 |
| neuropathy peripheralSignal | 1,904 | 12.6 | 12.1 | 20,035 |
| thrombocytopeniaSignal | 1,807 | 10.1 | 9.7 | 14,725 |
| neutropeniaSignal | 1,428 | 6.6 | 6.2 | 6,691 |
| disease progressionSignal | 1,072 | 5.6 | 5.3 | 4,081 |
| anaemiaSignal | 1,136 | 3.7 | 3.5 | 2,244 |
| toxicity to various agentsSignal | 918 | 3.4 | 3.2 | 1,541 |
| pneumoniaSignal | 1,575 | 3.0 | 2.9 | 2,148 |
| off label useSignal | 3,253 | 2.3 | 2.2 | 2,492 |
| pyrexia | 980 | 1.8 | 1.6 | 322 |
| diarrhoea | 1,414 | 1.4 | 1.3 | 136 |
| death | 1,591 | 1.1 | 1.1 | 29 |
| drug ineffective | 2,307 | 1.1 | 1.0 | 16 |
| fatigue | 1,162 | 0.9 | 0.9 | 8 |
| nausea | 925 | 0.7 | 0.7 | 102 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.